• No results found

Regulation of T cell responses in atherosclerosis Puijvelde, G.H.M. van

N/A
N/A
Protected

Academic year: 2021

Share "Regulation of T cell responses in atherosclerosis Puijvelde, G.H.M. van"

Copied!
9
0
0

Bezig met laden.... (Bekijk nu de volledige tekst)

Hele tekst

(1)

Citation

Puijvelde, G. H. M. van. (2007, June 28). Regulation of T cell responses in atherosclerosis.

Retrieved from https://hdl.handle.net/1887/12149

Version: Corrected Publisher’s Version

License: Licence agreement concerning inclusion of doctoral thesis in the

Institutional Repository of the University of Leiden

Downloaded from: https://hdl.handle.net/1887/12149

Note: To cite this publication please use the final published version (if applicable).

(2)

Regulation of T cell responses in atherosclerosis

(3)
(4)

Regulation of T cell responses in atherosclerosis

PROEFSCHRIFT

ter verkrijging van

de graad van Doctor aan de Universiteit Leiden,

op gezag van de Rector Magnificus prof.mr. P.F. van der Heijden, volgens besluit van het College voor Promoties

te verdedigen op donderdag 28 juni 2007 klokke 15.00 uur

door

Gijsbrecht Henricus Maria van Puijvelde

geboren te Terneuzen in 1978

(5)

The studies described in this thesis were supported by a grant of the Nether- lands Heart Foundation (NHF-2000T040) and were performed at the Division of Biopharmaceutics, Leiden/Amsterdam Center for Drug Research, Leiden University, Leiden, the Netherlands. Financial support by the Netherlands Heart Foundation for publication of this thesis is gratefully acknowledged.

The realization of this thesis was also financially supported by:

- Leiden University - J.E. Jurriaanse Stichting - LACDR

- Bristol-Myers Squibb - Dr. Ir. van de Laar Stichting

(6)

Luctor et Emergo

”Ik worstel en kom boven”

Zeeland - 1585

Aan mijn ouders voor Elze

(7)
(8)

Table of Contents

Page

Chapter 1 General Introduction 9

Chapter 2 Induction of oral tolerance to oxidized LDL ameliorates atherosclerosis

39

Chapter 3 Induction of oral tolerance to HSP60 or an HSP60- peptide activates T cell regulation and reduces atherosclerosis

55

Chapter 4 Immunotherapy of atherosclerosis using dendritic cells

71

Chapter 5 The effect of NKT cell activation on atherosclerosis depends on apoE and lipid loading

87

Chapter 6 Immunomodulation with OCH-pulsed dendritic cells attenuates atherosclerosis

101

Chapter 7 Effect of deficiency in the natural killer T cell specific Vα14-Jα281 receptor on atherosclerosis in LDL recep- tor deficient mice

119

Chapter 8 Summary and perspectives 131

Nederlandse samenvatting 145

List of abbreviations 151

List of publications 153

Curriculum Vitae 157

Nawoord 159

(9)

Referenties

GERELATEERDE DOCUMENTEN

This was already successful in several other publications in which oral and nasal tolerance to HSP65 and β2GPI protected against lesion formation in LDLr -/- mice 77,78,96 ,

In conclusion, oxLDL-specific T cells, present in LDLr -/- mice and important contributors in the immune response leading to the atherosclerotic plaque, can be counteracted

In addition, an increased production of IL-10 and TGF-β by mesenteric lymph node cells in response to HSP60 was observed, while splenocytes from HSP60-treated mice proliferated

In addition, we also showed that the serum of mice treated with oxLDL-pulsed DCs reduced the formation of foam cells as compared to serum from PBS-treated mice or mice treated

Activation of NKT cells via a combination of intraperitoneal and intra- venous injections of α-GalCer, resulted in a 84% reduction of lesion formation in LDLr -/- mice in

In contrast, injection of OCH-pulsed mDCs in low density lipo- protein receptor (LDLr) deficient mice reduced atherosclerotic plaque formation which may be explained by a

In conclusion we describe in this study that the initial effect of NKT cells on atherosclerosis may be due to an activation of NKT cells by a ligand present in LDLr -/- mice

Several critical steps are indicated by numbers: I=suggested atherosclerosis-promoting effect of NKT cell activation by lipids II=intraperitoneal and intravenous injection of